Results 51 to 60 of about 9,490 (159)

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source

The Biological Basis of the Merlin CP‐GEP Assay: Integrin Signaling and Early Metastatic Competence in Cutaneous Melanoma

International Journal of Dermatology, EarlyView.
Merlin CP‐GEP integrates mechanistic insights into a clinically actionable assay to predict SLN metastasis risk and inform personalized management of cutaneous melanoma. ABSTRACT The recent inclusion of the Merlin clinicopathologic–gene expression profile (CP‐GEP) assay in the National Comprehensive Cancer Network (NCCN) Melanoma Guidelines represents ...
Frank Z. Jing, Alexander Meves
wiley   +1 more source

Testing for Non‐Severe Heritable Platelet Function Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Heritable platelet function disorders (HPFD) are a diverse group of bleeding disorders characterised by a primary qualitative defect in platelet function rather than platelet number. HPFD may be broadly categorised according to the severity of bleeding, with Glanzmann thrombasthenia and Bernard Soulier syndrome classically considered severe ...
Kate Burley, Naomi Cornish, Maria Molina Carretero, Sarah K. Westbury   +3 more
wiley   +1 more source

Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis

Nature Communications, 2020
Current inhibitors of platelet integrin αIIbβ3 cause excessive bleeding, which limited their clinical use in cardiac patients. Here the authors design pure orthosteric αIIbβ3 inhibitors that prevent platelet aggregation and thrombosis without causing ...
Brian D. Adair, José L. Alonso, Johannes van Agthoven, Vincent Hayes, Hyun Sook Ahn, I-Shing Yu, Shu-Wha Lin, Jian-Ping Xiong, Mortimer Poncz, M. Amin Arnaout   +9 more
doaj   +1 more source

Heterodimeric Protein Surface‐Coupling Platform: Immobilization of Conformation Switchable and Functional αIIbβ3 Integrin

Advanced Materials Interfaces, 2023
Many biotechnologies require direct contact between biomolecules and (semi)solid substrates. However, little information is available regarding site‐directed covalent surface immobilization of heterodimeric proteins.
Miguel A. D. Neves, Sladjana Slavkovic, Yiming Wang, Yfke Pasman, Aron A. Shoara, Reid C. Gallant, Guangheng Zhu, Pasquale Benvenuto, Philip E. Johnson, Michael Thompson, Heyu Ni   +10 more
doaj   +1 more source

Inhibition of αIIbβ3 Ligand Binding by an αIIb Peptide that Clasps the Hybrid Domain to the βI Domain of β3. [PDF]

PLoS ONE, 2015
Agonist-stimulated platelet activation triggers conformational changes of integrin αIIbβ3, allowing fibrinogen binding and platelet aggregation. We have previously shown that an octapeptide, p1YMESRADR8, corresponding to amino acids 313-320 of the β ...
Wen Hwa Lee, Elisabeth Schaffner-Reckinger, Demokritos C Tsoukatos, Kelly Aylward, Vassilios Moussis, Vassilios Tsikaris, Paraskevi Trypou, Marion Egot, Dominique Baruch, Nelly Kieffer, Christilla Bachelot-Loza   +10 more
doaj   +1 more source

A functionally distinct HPA‐1a‐specific alloantibody associated with fetal/neonatal alloimmune thrombocytopenia that activates platelets via FcγRIIa

Transfusion, EarlyView.
Abstract Background Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is caused by maternal alloantibodies directed against fetal platelet antigens, most commonly human platelet antigen‐1a (HPA‐1a). These antibodies mediate platelet destruction and can lead to fetal and neonatal thrombocytopenia severe enough to cause life‐threatening organ bleeds ...
Huiying Zhi, Cathy Paddock, Daniel Villalobos‐Garcia, Janita Oosterhoff, Heng Zhang, Gestur Vidarsson, Renren Wen, Jieqing Zhu, Debra Newman, Peter J Newman   +9 more
wiley   +1 more source

Identification of a novel high‐prevalence red blood cell antigen on junctional adhesion molecule‐A defines a new blood group system

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Availability of new technologies has accelerated the pace of blood group discovery, with nine of 48 known systems being discovered in the past 5 years alone, and yet uncharacterized antigens remain. This study involved investigations of samples from a female patient presenting with a moderate strength pan‐reactive ...
Tosti J. Mankelow, Louise A. Tilley, Vanja Karamatic Crew, Benjamin Jones, Marina Izak, Liora Muncher, Vered Yahalom, Nicole M. Thornton   +7 more
wiley   +1 more source

From Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery

Advanced Healthcare Materials, Volume 15, Issue 37, 9 October 2026.
Biologically derived and hybrid nonviral nanovectors are examined as distinct but convergent design approaches. Integrating synthetic components with biologically functionalized membranes allows efficient interactions with complex cellular environments.
Clara Baldari, Claudia Leone, Gabriella Leccese, Claudia De Stradis, Alessandra Invidia, Concetta Quintarelli, Biagio De Angelis, Franco Locatelli, Giuseppe Gigli, Gabriele Maiorano, Ilaria Elena Palamà   +10 more
wiley   +1 more source

Mechanistic Basis for the Binding of RGD- and AGDV-Peptides to the Platelet Integrin αIIbβ3

, 2020
© 2017 American Chemical Society.Binding of soluble fibrinogen to the activated conformation of the integrin αIIbβ3 is required for platelet aggregation and is mediated exclusively by the C-terminal AGDV-containing dodecapeptide (γC-12) sequence of the ...
Weisel J., Klochkov V., Litvinov R., Barsegov V., Kononova O., Bennett J., Blokhin D.   +6 more
core